their risk of liver cirrhosis and hepatocellular carcinoma. There is a vaccine to prevent new infections, but no efficient cure for chronic infection. New insights into HBV biology are needed to improve cure rates for this widespread devastating disease. We describe a method to initiate replication of HBV, a DNA virus, using synthetic RNA. This approach has several advantages over existing systems: it eliminates contaminating background signal from input virus or plasmid DNA and can be easily adapted to multiple genotypes and mutants. Further, it can be applied to identify anti-HBV compounds, measure anti-HBV drug efficiency, study virus evolution, and, as we demonstrate, it can be uniquely applied to predict antiviral drug resistance.
cytokine that elicits a broad antiviral response-and orally administered nucleoside/nucleotide analogs. IFNα therapy can cure ~10% of patients, but it elicits often intolerable side effects and since few patients benefit, it is seldom used. In contrast, nucleoside/nucleotide analogs that effectively suppress HBV replication are well tolerated, but they do not eliminate the virus and therefore therapy is indefinite and often lifelong. New therapies are critically needed to improve HBV cure rates.
Lately, there has been renewed interest in curing chronic HBV. This has been driven, in part, by recent success in curing chronic hepatitis C virus infection and by the discovery of the HBV entry receptor, NTCP (4, 5), which has made it possible to study the full HBV lifecycle in cell culture. As a result, there is a growing belief that with new anti-HBV therapies and armed with a better understanding of HBV biology, curing chronic HBV may be within reach.
But despite progress, existing cell culture-based methods to study HBV have several limitations. For one, infection in vitro requires a high virus particle to cell ratio which results in a high background of contaminating viral DNA and protein from the inoculum. Background contamination also plagues methods that initiate HBV replication with either plasmid DNA transfection or using cell clones with integrated HBV genomes. In these cases, much of the viral RNA and protein originate not from the authentic viral template, cccDNA, but from either the transfected plasmid or integrated DNA. In fact, expression of viral RNAs and proteins is high even when the HBV genome encodes catalytically inactive HBV polymerase (Fig.S2 ).
To address these challenges, we developed a method to initiate HBV replication with in vitro-transcribed RNA. The HBV genome is reverse transcribed from an RNA templatepregenomic RNA (pgRNA)-and we reasoned that initiating replication and gene expression with RNA would have several benefits over systems that initiate replication with plasmid or integrated DNA. Initiating replication with RNA would, for example, eliminate contaminating HBV DNA that confounds qPCR reactions, and since not all viral RNAs are required to initiate replication, some viral proteins (e.g. HBsAg, a commonly used marker for infection) would be produced only if the viral lifecycle progressed and cccDNA was established.
We chose to launch HBV replication with pgRNA alone since pgRNA is not only the template for reverse transcription, but also the template for translation of the HBV core and polymerase (Pol) proteins, both of which are required for reverse transcription (Fig. S3 ). The idea to initiate HBV with pgRNA is supported by previous work on a relative of HBV, duck hepatitis B virus (DHBV), with the observation that DHBV pgRNA can initiate infection in cultured cells (6).
Figure 1
demonstrates that transfected HBV pgRNA is translated to produce the core protein (HBcAg), reverse transcribed by the viral polymerase (Pol), and transported to the nucleus to form cccDNA, yielding HBsAg expression. Southern blot on Hirt-extracted DNA isolated from pgRNA-transfected cells confirms that pgRNA gives rise to cccDNA. Transfection of pgRNA encoding a catalytically inactive Pol mutant (YMHD) demonstrates that the HBV DNA and HBsAg signal is replication dependent and that there is minimal to no contaminating background signal from input RNA.
Until recently, most HBV cell culture studies have focused on genotypes A and D.
Similarly, our initial work was performed with genotype A HBV. There are, however, additional HBV genotypes, several of which are highly prevalent in various parts of the world ( Fig. 2A and table S1) (7). It is increasingly recognized that studying multiple genotypes is important, since not all HBV genotypes respond equally well to anti-HBV therapies (8). We next tested whether the RNA launch method could be used to study multiple HBV genotypes. For this, we cloned representative pgRNA sequences for HBV genotypes B-H downstream of a T7 promoter and in vitro-transcribed pgRNAs. We found that transfected pgRNA from all eight HBV genotypes yielded HBV DNA and all but genotype G yielded HBsAg (Fig. 2B-C) . As expected, the signal is replication dependent since the reverse transcriptase inhibitor, entecavir (ETV), decreases HBV DNA levels and eliminates HBsAg production. This demonstrates that the RNA launch method can be applied to study multiple HBV genotypes and viral mutants without the high background signal typical of plasmid transfection and virus infection approaches. Further, this approach could be used to bypass virus entry and study how genotype differences affect post-entry steps in the virus lifecycle. For example, genome amplification, accumulation of replication intermediates, and cccDNA formation. Indeed, the results in Fig. 2 and S4) indicate there are differences in reverse transcription and HBsAg production among genotypes that can be further explored with this system. We next tested whether the RNA launch method could be used to compare the potency and effectiveness of anti-HBV inhibitors. For this, we compared three reverse transcriptase inhibitors known to inhibit HBV: ETV, tenofovir disoproxil fumarate (TDF), and lamivudine (LAM). As shown in Fig. 3A and Table S2 , all three drugs inhibited HBV replication in a dose-dependent manner, demonstrating that the RNA launch method can be used to study the efficacy of anti-HBV compounds in a simple and easy-to-use assay. These results also suggest that the method could be used as a screening tool to discover novel HBV inhibitors.
Given the low background from input pgRNA, we next asked whether we could use the system to select for drug-resistance mutations. Identifying drug-resistance mutations can provide drug developers with useful information for prioritizing or down selecting compounds and compound series for further development. Moreover, it can provide insight into drug-protein interactions and be used as an iterative approach with new chemistry to improve the resistance profile of a compound series. However, selecting drug resistance mutations for HBV is challenging since the virus spreads too poorly in vitro for drug-resistant variants to emerge. Consequently, there is no cell culture-based method to assess antiviral resistance for anti-HBV compounds; however, with new anti-HBV drugs currently undergoing preclinical and clinical evaluation, there is a high demand for methods to assess drug resistance.
We reasoned that several features of the RNA launch method would enable us to enrich HBV drug-resistant variants. For one, unlike protocols that initiate infection with plasmid DNA, sequence diversity is inherent in the pgRNA population. This is because T7 polymerase, which we use to transcribe HBV pgRNA, has an error rate of ~10 -4 ( Fig. S5B ) and therefore produces a diverse mixture of sequence variants immediately available for selection (9). Also, since transfecting pgRNA bypasses the entry step, cells likely sample more genomes than they would with other HBV systems that initiate infection with virus particles. And further, since drugresistant genomes can be enriched by PCR without contamination from input plasmid or viral DNA, we reasoned it would be possible to identify mutations that confer drug resistance by deep sequencing. This concept is outlined in Fig. S5A .
As a proof-of-concept for this approach, we tested whether we could enrich for LAM resistance mutations from in vitro-transcribed pgRNA. Two days after transfecting Huh-7.5-NTCP cells in triplicate with pgRNA we harvested virus-containing cell supernatants and isolated viral DNA. Viral DNA was then amplified by PCR ( Fig. S4C ) and sequenced by MiSeq. Remarkably, we found that with only a single round of selection, the two most common clinically-relevant LAM-resistance mutations, M204V and M204I, were enriched in the population ( Fig. 3B) (10).
This demonstrates that the RNA launch method can be used to identify mutations that confer drug resistance. For antivirals with high resistance barriers this approach can be modified to include mutagenized templates and mutant polymerases with higher error rates to increase sequence diversity. This approach can also be combined with deep mutational analysis and applied to study viral evolution under various selective pressures beyond anti-HBV drugs.
Altogether, the RNA launch method is a unique and versatile new tool to study basic HBV biology, identify novel anti-HBV inhibitors, and inform drug development.
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Materials

Plasmids
All plasmid sequences used in this study have been uploaded to GenBank (table S1). Briefly, HBV pgRNA sequences were cloned into the pGEM-3Z plasmid backbone immediately downstream of a T7 promoter. The genotype A sequence has been previously described as serotype adw2 (11). Genotype D was derived from the HepDE19 cell line (12). Genotypes B, C, and E-H were derived from over-length HBV constructs originally cloned by Stephan Schäfer (13) and then subcloned into the pGEM3Z plasmid backbone. The HBV-YMHD Polymerase mutant was made in the genotype A backbone.
Cells
Huh-7.5-NTCP cells were made as previous described for HepG2-NTCP (14) 
RNA transfection
Huh-7.5-NTCP cells were seeded at 2.5 x 10 5 cells per well in 6 well plates two days before transfection. The media was changed to 2 ml DMEM containing 1.5% FBS and 0.1 mM NEAA just before transfection. For each transfected well, 1 µg HBV pgRNA was mixed with 5 µl Lipofectamine TM 2000 (Fisher Scientific, cat. #11668019) in 500 µl Opti-MEM Reduced Serum Medium (Fisher Scientific, cat. #51985034) and incubated at room temperature for 20 min. The mixture was then added to cells and spinoculated by centrifugation at 1000 x g for 30 min at 37ºC. Six hours later the media was removed and replaced with DMEM containing 10% FBS and 0.1 mM NEAA.
DNA transfection
To detect HBsAg produced by plasmid transfection from genotypes A-H (table S1), Huh7.5-NTCP cells were seeded at 2.5 x 10 5 cells per well in 6-well plates and transfected two days later in DMEM containing 1.5% FBS and 0.1 mM NEAA with 2.5 µg of plasmid DNA using X-tremeGENE™ 9 DNA transfection reagent (Sigma cat. #6365779001) at 5:1 reagent:DNA ratio.
Supernatants were collected four days post transfection for HBsAg CLIA. To compare features of the RNA launch to plasmid transfection (Fig. S2) , a 1.3xHBV plasmid (genotype A) (15) was transfected into HepG2-NTCP cells. Cells were seeded at 7 x 10 4 cell/well in collagen-coated 24well plates and transfected with 0.5 µg DNA the following day using Lipofectamine TM 2000 at 3:1 reagent:DNA ratio. Two days post transfection, cells and supernatants were collected for analysis. To compare features of the RNA launch to HepDE19 cells (Fig. S2 ), HepDE19 cells were seeded at 7 x 10 4 cell/well in collagen-coated 24-well plates in media containing 2 µg/ml tetracycline. The following day media was changed and replaced with media with and without tetracycline. Five days later supernatants and cells were collected for analysis.
Analysis of HBV translation and replication
HBsAg was quantified using a chemiluminescence immunoassay (CLIA) kit (Autobio Diagnostics Co., Zhengzhou, China) according to the manufacturer's instructions. HBsAg experiments were performed in 24-well format. To quantify HBV DNA, total DNA was extracted from individual wells of 6-well plates using QIAamp DNA Blood Mini Kit (Qiagen, cat. #51106) and HBV DNA was detected by qPCR as previously described (14). In addition, we designed a separate set of primers targeting the HBV Core region of genotype A that we used in SYBR green assays. Both assays gave similar results; however, the SYBR assay more consistently yielded a background signal (YMHD polymerase mutant) below the limit of quantification. Primers and probe sequences for qPCR are listed in table S3 . For immunofluorescence analysis, cells were stained with Anti-HBc (Austral Biologicals, cat. #HBP-023-9) at 1:500 dilution or Anti-HBs (Abcam, cat# ab9193) at 1:500 dilution. Fluorescent images were quantified in ImageJ (NIH, Bethesda, Maryland) using the thresholding method, similar to what has been previously described (16). Southern blot was performed combining two protocols previously described (15, 17) with the several modifications. HBV cccDNA was enriched by Hirt extraction as previously described (17) 
HBV inhibitor treatment
Entecavir was purchased from Cayman Chemical Company (cat. #209216-23-9), lamivudine was purchased from Sigma (cat. #L1295), and tenofovir disoproxil fumarate was obtained through the AIDS Reagent Program, Division of AIDS, NIAID, NIH. Huh-7.5-NTCP cells were seeded at 1 x 10 4 cells per well in 96-well plates two days before transfection. One day before transfection, media was changed and replaced with 100 µl DMEM containing 10% FBS and 0.1 mM NEAA with HBV inhibitors or vehicle control. The following day, each well was transfected as described above with 34 ng of HBV pgRNA in media containing drug. Six hours later, media was changed and replaced with drug-containing media. Every two days, media was collected and replaced and 50 µl of collected supernatants were used for HBsAg CLIA, as described above.
Enriching LAM-resistant viral variants
To enrich mutations that confer LAM resistance, 2.5 x 10 5 Huh-7.5-NTCP cells were seeded two days before pgRNA transfection as described above. The cells were treated with 400 µM LAM 24 h before RNA transfection. Transfection was performed and cells were maintained in the presence of 400 µM LAM. Supernatant was collected two days after transfection and concentrated with Amicon-Ultra-0.5 ml 100 kDa centrifugal filters (Millipore, cat. 
